| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Developmental Chemotherapy [J. R. F. M., C. W. Y., R. P. W.] and Leukemia Services [S. R. F., R. P. W.], Department of Medicine, and the Laboratory of Clinical Pharmacology [J. R. F. M., C. W. Y.], Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, New York, and Hoffmann-La Roche Inc. [C. H., F. D., W. A. G.], Nutley, New Jersey
All-trans retinoic acid (RA) induces leukemic cell differentiation and complete remission in a high proportion of patients with acute promyelocytic leukemia (APL). However, remissions induced by all-trans RA tend to be brief, and relapses are associated with resistance to further treatment in vivo, although the leukemic cells appear to retain sensitivity to the cytodifferentiating effects of all-trans RA in vitro.
The clinical pharmacology of all-trans RA was examined in 13 patients with APL. The drug was administered at a constant dose of 45 mg/m2/day, given as a single dose on the first day of therapy and in two divided doses thereafter. Plasma and urinary concentrations of the parent drug and metabolites were quantitated by reverse-phase high-performance liquid chromatography and, where required, by a combination of normalphase liquid chromatography/negative chemical ionization mass spectrometry. In patients with APL, basal levels of endogenous retinol and natural retinoids were within the normal range. Peak plasma levels of all-trans RA (347 ± 266 ng/ml, mean ± SD) were reached 1–2 h after drug ingestion and decayed in a monoexponential fashion with a half-life of 0.8 ± 0.1 h. The only drug metabolite detected in plasma or urine was 4-oxo-all-trans RA (present in urine as the glucuronide conjugate). This metabolite accounted for <10% of the circulating drug in plasma, and its cumulative urinary excretion accounted for <1% of the administered dose. The drug was not found in cerebrospinal fluid.
Continued oral administration of all-trans RA was associated with a significant decrease in both the plasma peak levels and the area under the concentration-time curve (P = 0.01 and 0.004, respectively) when measured after 2–6 weeks of treatment. We previously reported that a decrease in plasma area under the concentration-time curve was highly correlated with clinical relapse. Observations in a subset of patients in this study suggested that, in fact, the major decrease occurred early, within the first 7 days of treatment. These changes were associated with a 10-fold increase in urinary excretion of 4-oxo-all-trans RA glucuronide, suggesting that the accelerated clearance from plasma was associated with increased drug catabolism.
The rapid disappearance may explain early relapse from remissions induced by all-trans RA; clinical "resistance" to all-trans RA may either wholly or in part result from an inability to sustain effective plasma concentrations of all-trans RA during continuous treatment. Induction of accelerated catabolism by a cytochrome P-450-like enzyme system could account for this phenomenon; however, alternative explanations, particularly a drug-induced increase in cellular retinoic acid-binding proteins in normal tissue, cannot be excluded. Results from this study suggest that treatment with all-trans RA in APL might be improved by discontinuous dosing schedules or by concurrent treatment with P-450 enzyme inhibitors.
1 Supported in part by grants FD-R-000674 from the Food and Drug Administration, and by CA-08748 and CA-05826 from the National Cancer Institute, Department of Health and Human Services. Presented in part at the annual meeting of the American Society of Clinical Oncology, May 1991.
2 To whom requests for reprints should be addressed, at Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.
Received 11/12/91. Accepted 2/11/92.
This article has been cited by other articles:
|
|
 |
|
  M. Camacho, C. Rodriguez, J. Salazar, J. Martinez-Gonzalez, J. Ribalta, J.-R. Escudero, L. Masana, and L. Vila Retinoic acid induces PGI synthase expression in human endothelial cells J. Lipid Res., August 1, 2008; 49(8): 1707 - 1714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kesari, J. Drappatz, S. Akar, J.-A. Vergilio, P. Y. Wen, R. J. Soiffer, R. M. Stone, and D. J. DeAngelo Recurrent Acute Promyelocytic Leukemia Presenting As a Sacral Nerve Root Mass J. Clin. Oncol., July 1, 2008; 26(19): 3279 - 3281. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Wang, X. Ma, K. W. Krausz, J. R. Idle, and F. J. Gonzalez Role of Pregnane X Receptor in Control of All-Trans Retinoic Acid (ATRA) Metabolism and Its Potential Contribution to ATRA Resistance J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 674 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Muindi, M. D. Roth, R. A. Wise, J. E. Connett, G. T. O'Connor, J. W. Ramsdell, N. W. Schluger, M. Romkes, R. A. Branch, F. C. Sciurba, et al. Pharmacokinetics and Metabolism of All-trans- and 13-cis-Retinoic Acid in Pulmonary Emphysema Patients J. Clin. Pharmacol., January 1, 2008; 48(1): 96 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Raanani, O Shpilberg, and I Ben-Bassat Extramedullary disease and targeted therapies for hematological malignancies--is the association real? Ann. Onc., January 1, 2007; 18(1): 7 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mirza, M. Fishman, I. Fricke, M. Dunn, A. M. Neuger, T. J. Frost, R. M. Lush, S. Antonia, and D. I. Gabrilovich All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients. Cancer Res., September 15, 2006; 66(18): 9299 - 9307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Osanai and M. Petkovich Expression of the Retinoic Acid-Metabolizing Enzyme CYP26A1 Limits Programmed Cell Death Mol. Pharmacol., May 1, 2005; 67(5): 1808 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Kim and R. Lotan Identification of Retinoid-Modulated Proteins in Squamous Carcinoma Cells Using High-Throughput Immunoblotting Cancer Res., April 1, 2004; 64(7): 2439 - 2448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Westervelt, J. L. Pollock, K. M. Oldfather, M. J. Walter, M. K. Ma, A. Williams, J. F. DiPersio, and T. J. Ley Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia PNAS, July 9, 2002; 99(14): 9468 - 9473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Marill, T. Cresteil, M. Lanotte, and G. G. Chabot Identification of Human Cytochrome P450s Involved in the Formation of All-trans-Retinoic Acid Principal Metabolites Mol. Pharmacol., April 13, 2001; 58(6): 1341 - 1348. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. I Axel, A. Frigge, J. Dittmann, H. Runge, I. Spyridopoulos, R. Riessen, R. Viebahn, and K. R Karsch All-trans retinoic acid regulates proliferation, migration, differentiation, and extracellular matrix turnover of human arterial smooth muscle cells Cardiovasc Res, March 1, 2001; 49(4): 851 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Idres, G. Benoît, M. A. Flexor, M. Lanotte, and G. G. Chabot Granulocytic Differentiation of Human NB4 Promyelocytic Leukemia Cells Induced by All-trans Retinoic Acid Metabolites Cancer Res., January 1, 2001; 61(2): 700 - 705. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Douer, E. Estey, S. Santillana, J. M. Bennett, G. Lopez-Bernstein, K. Boehm, and T. Williams Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid Blood, January 1, 2001; 97(1): 73 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ikezoe, E. S. Daar, J.-i. Hisatake, H. Taguchi, and H. P. Koeffler HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells Blood, November 15, 2000; 96(10): 3553 - 3559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Stoppie, M. Borgers, P. Borghgraef, L. Dillen, J. Goossens, G. Sanz, H. Szel, C. Van Hove, G. Van Nyen, G. Nobels, et al. R115866 Inhibits All-trans-Retinoic Acid Metabolism and Exerts Retinoidal Effects in Rodents J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 304 - 312. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. M. Samokyszyn, W. E. Gall, G. Zawada, M. A. Freyaldenhoven, G. Chen, P. I. Mackenzie, T. R. Tephly, and A. Radominska-Pandya 4-Hydroxyretinoic Acid, a Novel Substrate for Human Liver Microsomal UDP-glucuronosyltransferase(s) and Recombinant UGT2B7 J. Biol. Chem., March 15, 2000; 275(10): 6908 - 6914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Park, W. C. Gray, I. Hernandez, M. Jacobs, R. A. Ord, M. Sutharalingam, R. G. Smith, D. A. Van Echo, S. Wu, and B. A. Conley Phase I Trial of All-Trans Retinoic Acid in Patients with Treated Head and Neck Squamous Carcinoma Clin. Cancer Res., March 1, 2000; 6(3): 847 - 854. [Abstract] [Full Text]
|
|
|
|
 |
|
 B Nicke, E-O Riecken, and S Rosewicz Induction of retinoic acid receptor beta mediates growth inhibition in retinoid resistant human colon carcinoma cells Gut, July 1, 1999; 45(1): 51 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lanvers, G. Hempel, G. Blaschke, and J. Boos Chemically induced isomerization and differential uptake modulate retinoic acid disposition in HL-60 cells FASEB J, December 1, 1998; 12(15): 1627 - 1633. [Abstract] [Full Text]
|
|
|
|
|
|
Z von Marschall, E O Riecken, and S Rosewicz Stromelysin 3 is overexpressed in human pancreatic carcinoma and regulated by retinoic acid in pancreatic carcinoma cell lines Gut, November 1, 1998; 43(5): 692 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Ding, Y.-P. Li, L. M. Nobile, G. Grills, I. Carrera, E. Paietta, M. S. Tallman, P. H. Wiernik, and R. E. Gallagher Leukemic Cellular Retinoic Acid Resistance and Missense Mutations in the PML-RARalpha Fusion Gene After Relapse of Acute Promyelocytic Leukemia From Treatment With All-trans Retinoic Acid and Intensive Chemotherapy Blood, August 15, 1998; 92(4): 1172 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-j. M. van der Leede, C. E. van den Brink, W. W. M. Pijnappel, E. Sonneveld, P. T. van der Saag, and B. van der Burg Autoinduction of Retinoic Acid Metabolism to Polar Derivatives with Decreased Biological Activity in Retinoic Acid-sensitive, but Not in Retinoic Acid-resistant Human Breast Cancer Cells J. Biol. Chem., July 18, 1997; 272(29): 17921 - 17928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. White, Y.-D. Guo, K. Baetz, B. Beckett-Jones, J. Bonasoro, K. E. Hsu, F. J. Dilworth, G. Jones, and M. Petkovich Identification of the Retinoic Acid-inducible All-trans-retinoic Acid 4-Hydroxylase J. Biol. Chem., November 22, 1996; 271(47): 29922 - 29927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Adamson All-Trans-Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia Oncologist, October 1, 1996; 1(5): 305 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Warrell, H. de The, Z.-Y. Wang, and L. Degos Acute Promyelocytic Leukemia N. Engl. J. Med., July 15, 1993; 329(3): 177 - 189. [Full Text]
|
|
|
|
|
|
A. Radominska-Pandya, G. Chen, P. J. Czernik, J. M. Little, V. M. Samokyszyn, C. A. Carter, and G.{m. d.}y. Nowak Direct Interaction of All-trans-retinoic Acid with Protein Kinase C (PKC). IMPLICATIONS FOR PKC SIGNALING AND CANCER THERAPY J. Biol. Chem., July 14, 2000; 275(29): 22324 - 22330. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
